INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Emergent BioSolutions (NYSE:EBS)

Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 18, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

The Schall Law Firm

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83182

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

Los Angeles, California--(Newsfile Corp. - May 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE:EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 18, 2021.

If you are a shareholder who suffered a loss, click here to participate.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Emergent BioSolution's Baltimore facility had a pattern of manufacturing problems resulting in an increased likelihood of product contamination. The company suffered from a string of FDA citations due to the poor quality of its Baltimore operations. The Company was forced to discard the equivalent of millions of COVID-19 vaccine doses after the plant deviated from standard procedures. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Emergent BioSolutions, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

The Schall Law Firm

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83182

EBSEmergent BioSolutions Inc

$10.82-1.99%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.